Israel Englander Citius Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 2,048,860 shares of CTXR stock, worth $717,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,048,860

Holding current value

$717,101

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.58 - $1.03 $1.19 Million - $2.11 Million	2,048,860 New	2,048,860 $1.19 Million
Q2 2023 Aug 14, 2023	SELL	$1.08 - $1.65 $261,151 - $398,981	-241,807 Reduced 79.42%	62,675 $75,000
Q1 2023 May 15, 2023	SELL	$0.78 - $1.42 $192,382 - $350,234	-246,644 Reduced 44.75%	304,482 $356,000
Q4 2022 Feb 14, 2023	SELL	$0.79 - $1.28 $184,586 - $299,077	-233,654 Reduced 29.77%	551,126 $435,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $1.33 $133,761 - $1.27 Million	-955,440 Reduced 54.9%	784,780 $950,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.87 $1.53 Million - $3.25 Million	1,740,220 New	1,740,220 $1.6 Million
Q2 2021 Aug 16, 2021	SELL	$1.51 - $4.23 $253,873 - $711,181	-168,128 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.04 - $2.34 $164,404 - $369,909	158,081 Added 1573.41%	168,128 $299,000
Q4 2020 Feb 16, 2021	BUY	$0.9 - $1.2 $9,042 - $12,056	10,047 New	10,047 $10,000
Q4 2017 Feb 14, 2018	SELL	$2.65 - $5.1 $52,954 - $101,913	-19,983 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.69 - $4.03 $53,754 - $80,531	19,983	19,983 $63,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

30.6M

Call Options Held

24.7K

Put Options Held

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $51.1M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account